Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2836)	6/23/2010 1:14:14 PM
From: Jibacoa	1 Recommendation Read Replies (1) \| Respond to of 3722

ZGEN is up today, trying to get off from its near tern DT.<g> The stock is benefiting from a report at UBS, wher it had an "upgrade" from hold to Buy.<g> The stock is up 7.33% on volume of > 506 Ks, which is > 1.5x its ADV bigcharts.marketwatch.com The ACTAY is $6.90 The UBS analyst reaffirmed its "target" of $6.50 But the stock has a good amount of resistance at the $4.90 to $5 levels and also at $5.55 before testing the more important looking one at the $6 level.<g> bigcharts.marketwatch.com However, if ZGEN could get good reports on its PII of PEG-IFN-lambda for the treatment of hepatitis C and its PII of IL-21 for treatment of metastatic melanoma, the stock could get to the $6 or maybe the $9 level.<g> bigcharts.marketwatch.com Bernard